首页 News 正文

Pfizer Announces Approval of Oral Migraine New Drug "Rimezepam orally disintegrating tablets" in China

我放心你带套猛
272 0 0

On January 26th, Pfizer announced that its new generation of specific migraine treatment drug, Rimezepam orally disintegrating tablets, has been approved by the National Medical Products Administration for the acute treatment of migraines in adults with or without aura. It is reported that this is a calcitonin gene related peptide (CGRP) receptor antagonist that uses orally disintegrating tablet technology. It can effectively block the key pathways related to the onset of migraine, quickly and continuously relieve headaches and related accompanying symptoms. It is easy to take and has no cardiovascular disease taboos or other effects.
Migraine is a common chronic disease, and the World Health Organization (WHO) lists it as one of the 10 most disabling internal medicine diseases. The typical feature of this disease is intermittent attacks that last for 4 to 72 hours, and may cause moderate to severe pulsatile headaches such as nausea, vomiting, fear of sound, and photophobia. At present, the common drugs for acute treatment of migraines are tratans. However, these drugs have side effects that cause vasoconstriction, so patients at risk of cardiovascular disease cannot use these drugs.
Remazepam sulfate orally disintegrating tablets were approved for marketing by the US FDA in 2020 for the acute treatment of adult migraine attacks. According to an earlier press release from Biohaven, this is the first CGRP receptor small molecule antagonist with a rapid oral disintegration tablet form. In 2021, the product was once again granted FDA expanded indications for the preventive treatment of episodic migraines (with less than 15 migraine attacks per month). In May 2022, Pfizer spent approximately $11.6 billion to acquire Biohaven to expand its migraine product pipeline, in order to acquire this product.
According to a Pfizer press release, Rimezepam orally disintegrating tablets are the first oral CGRP receptor antagonist to show positive results in a key trial in China. In this study, patients achieved the common primary endpoint of pain and most troubled symptom relief after a single oral dose of 75mg of medication for 2 hours. Patients can quickly relieve pain and eliminate the most troublesome symptoms within 45 minutes, restore normal function within 60 minutes, and eliminate pain within 90 minutes; For most patients, its sustained efficacy can reach 48 hours, while demonstrating good safety and tolerability, consistent with previous clinical trial results in the United States.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  •   知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
    caffycat
    昨天 11:18
    支持
    反对
    回复
    收藏
  •   每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
    star8699
    3 天前
    支持
    反对
    回复
    收藏
  •   上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
    goodfriendboy
    3 天前
    支持
    反对
    回复
    收藏
  •   人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
    3233340
    昨天 17:06
    支持
    反对
    回复
    收藏
我放心你带套猛 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    31